Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELOXNASDAQ:FRLNNASDAQ:PALINASDAQ:TTNP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELOXEloxx Pharmaceuticals$0.11$0.00▼$0.90N/A-1536.71,715 shsN/AFRLNFreeline Therapeutics$6.48$6.48$2.11▼$8.74$28.12M0.6612,055 shsN/APALIPalisade Bio$0.72-5.4%$0.73$0.60▼$5.15$3.47M1.46517,960 shs104,081 shsTTNPTitan Pharmaceuticals$4.52-2.3%$4.02$3.03▼$14.80$4.13M1.25138,515 shs836 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELOXEloxx Pharmaceuticals0.00%0.00%0.00%-99.99%-99.99%FRLNFreeline Therapeutics0.00%0.00%0.00%0.00%0.00%PALIPalisade Bio-5.49%+0.59%-1.39%-7.10%-83.92%TTNPTitan Pharmaceuticals-0.84%+6.57%+20.31%+17.86%-27.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELOXEloxx PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AFRLNFreeline TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APALIPalisade Bio2.5628 of 5 stars3.53.00.00.02.90.01.3TTNPTitan Pharmaceuticals0.9008 of 5 stars0.04.00.00.03.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELOXEloxx Pharmaceuticals 0.00N/AN/AN/AFRLNFreeline Therapeutics 0.00N/AN/AN/APALIPalisade Bio 3.00Buy$12.001,534.88% UpsideTTNPTitan Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest FRLN, TTNP, PALI, and ELOX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025PALIPalisade BioBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELOXEloxx PharmaceuticalsN/AN/AN/AN/AN/AN/AFRLNFreeline TherapeuticsN/AN/AN/AN/A$12.07 per shareN/APALIPalisade Bio$250K14.08N/AN/A$18.29 per share0.04TTNPTitan Pharmaceuticals$180K22.93N/AN/A$8.82 per share0.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELOXEloxx Pharmaceuticals-$36.06MN/A0.00N/AN/AN/AN/AN/AN/AFRLNFreeline Therapeutics-$88.97M-$5.59N/AN/AN/AN/A-150.46%-97.01%N/APALIPalisade Bio-$12.30M-$6.80N/AN/AN/AN/A-148.51%-115.16%8/11/2025 (Estimated)TTNPTitan Pharmaceuticals-$5.57M-$4.59N/A∞N/AN/A-118.01%-103.79%8/13/2025 (Estimated)Latest FRLN, TTNP, PALI, and ELOX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025TTNPTitan PharmaceuticalsN/A-$0.62N/A-$0.62N/AN/A5/12/2025Q1 2025PALIPalisade Bio-$0.84-$0.47+$0.37-$0.47N/AN/A3/24/2025Q4 2024PALIPalisade Bio-$2.39-$0.69+$1.70-$0.69N/AN/A3/20/2025Q4 2024TTNPTitan PharmaceuticalsN/A-$0.85N/A-$0.85N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELOXEloxx PharmaceuticalsN/AN/AN/AN/AN/AFRLNFreeline TherapeuticsN/AN/AN/AN/AN/APALIPalisade BioN/AN/AN/AN/AN/ATTNPTitan PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELOXEloxx PharmaceuticalsN/AN/AN/AFRLNFreeline TherapeuticsN/A1.95N/APALIPalisade BioN/A3.313.31TTNPTitan PharmaceuticalsN/A9.719.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELOXEloxx Pharmaceuticals2.90%FRLNFreeline Therapeutics46.26%PALIPalisade Bio11.79%TTNPTitan Pharmaceuticals31.49%Insider OwnershipCompanyInsider OwnershipELOXEloxx Pharmaceuticals20.20%FRLNFreeline Therapeutics1.90%PALIPalisade Bio3.28%TTNPTitan Pharmaceuticals0.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELOXEloxx Pharmaceuticals303.14 million2.51 millionNot OptionableFRLNFreeline Therapeutics1524.34 million4.26 millionNot OptionablePALIPalisade Bio104.80 million2.68 millionNot OptionableTTNPTitan Pharmaceuticals10914,000686,000OptionableFRLN, TTNP, PALI, and ELOX HeadlinesRecent News About These CompaniesTitan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred StockApril 11, 2025 | globenewswire.comTitan Pharmaceuticals: Q4 Earnings SnapshotMarch 20, 2025 | sfgate.comTitan Pharmaceuticals receives Nasdaq notice of non-complianceNovember 27, 2024 | markets.businessinsider.comTitan Pharmaceuticals Faces Nasdaq Compliance Challenges with Reporting and Audit Committee RequirementsNovember 27, 2024 | quiverquant.comTitan Pharmaceuticals, Inc. Announces Receipt of Notice from NasdaqNovember 27, 2024 | globenewswire.comSanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly BeatOctober 25, 2024 | msn.comTitan Pharmaceuticals, Inc. (TTNP)October 17, 2024 | finance.yahoo.com(TTNP) Technical Pivots with Risk ControlsSeptember 25, 2024 | news.stocktradersdaily.comWhen (TTNP) Moves Investors should ListenSeptember 15, 2024 | news.stocktradersdaily.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITI, FRZA, TTNP on Behalf of ShareholdersSeptember 9, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITI, CFB, TTNP, DFS on Behalf of ShareholdersSeptember 5, 2024 | stockhouse.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. – TTNPSeptember 5, 2024 | globenewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. - TTNPSeptember 4, 2024 | prnewswire.comTitan Pharmaceuticals Share Price (TTNP.US)August 24, 2024 | lse.co.ukShareholder Alert: Ademi LLP investigates whether Titan Pharmaceuticals, Inc. has obtained a Fair Price for its Public ShareholdersAugust 23, 2024 | prnewswire.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Titan Pharmaceuticals, Inc. MergerAugust 22, 2024 | markets.businessinsider.comCrude Oil Falls; Palo Alto Networks Shares Jump After Q4 EarningsAugust 21, 2024 | msn.comTitan Pharma enters into merger agreement with KE Sdn. Bhd.August 21, 2024 | pharmabiz.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TTNP, MCRB, LLAP on Behalf of ShareholdersAugust 20, 2024 | stockhouse.comTitan Pharmaceuticals Shares Double on Reverse Merger DealAugust 20, 2024 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFRLN, TTNP, PALI, and ELOX Company DescriptionsEloxx Pharmaceuticals NASDAQ:ELOXEloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.Freeline Therapeutics NASDAQ:FRLNFreeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.Palisade Bio NASDAQ:PALI$0.72 -0.04 (-5.42%) As of 01:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.Titan Pharmaceuticals NASDAQ:TTNP$4.51 -0.11 (-2.27%) As of 01:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
